HCA Healthcare, Inc. $HCA Position Cut by New York Life Investment Management LLC

New York Life Investment Management LLC lessened its position in HCA Healthcare, Inc. (NYSE:HCA) by 7.6% during the third quarter, Holdings Channel reports. The fund owned 22,262 shares of the company’s stock after selling 1,820 shares during the quarter. New York Life Investment Management LLC’s holdings in HCA Healthcare were worth $9,488,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Sovran Advisors LLC grew its holdings in HCA Healthcare by 1.0% in the 3rd quarter. Sovran Advisors LLC now owns 2,278 shares of the company’s stock worth $1,063,000 after buying an additional 22 shares in the last quarter. Hemington Wealth Management grew its stake in shares of HCA Healthcare by 11.0% in the third quarter. Hemington Wealth Management now owns 253 shares of the company’s stock worth $107,000 after purchasing an additional 25 shares in the last quarter. Abound Wealth Management raised its stake in shares of HCA Healthcare by 28.0% during the third quarter. Abound Wealth Management now owns 119 shares of the company’s stock valued at $51,000 after purchasing an additional 26 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC increased its stake in HCA Healthcare by 17.1% during the 3rd quarter. Annis Gardner Whiting Capital Advisors LLC now owns 185 shares of the company’s stock valued at $79,000 after buying an additional 27 shares during the period. Finally, Ballentine Partners LLC lifted its stake in shares of HCA Healthcare by 0.8% in the 3rd quarter. Ballentine Partners LLC now owns 3,693 shares of the company’s stock worth $1,574,000 after acquiring an additional 29 shares during the period. Institutional investors own 62.73% of the company’s stock.

HCA Healthcare Stock Performance

HCA Healthcare stock opened at $497.66 on Tuesday. The company has a 50 day moving average price of $479.86 and a 200 day moving average price of $444.46. HCA Healthcare, Inc. has a 52 week low of $295.00 and a 52 week high of $527.55. The firm has a market capitalization of $113.56 billion, a price-to-earnings ratio of 17.54, a P/E/G ratio of 1.54 and a beta of 1.36.

HCA Healthcare (NYSE:HCA) last issued its earnings results on Tuesday, January 27th. The company reported $8.01 EPS for the quarter, topping the consensus estimate of $7.37 by $0.64. The business had revenue of $19.51 billion during the quarter, compared to analysts’ expectations of $19.67 billion. HCA Healthcare had a negative return on equity of 409.11% and a net margin of 8.97%.HCA Healthcare’s revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the firm posted $6.22 earnings per share. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. Equities analysts forecast that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.

HCA Healthcare Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 17th will be issued a dividend of $0.78 per share. This is an increase from HCA Healthcare’s previous quarterly dividend of $0.72. This represents a $3.12 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Tuesday, March 17th. HCA Healthcare’s dividend payout ratio is 10.15%.

Insiders Place Their Bets

In other HCA Healthcare news, EVP Michael S. Cuffe sold 1,500 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $498.09, for a total value of $747,135.00. Following the completion of the sale, the executive vice president owned 30,003 shares in the company, valued at $14,944,194.27. This represents a 4.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.30% of the company’s stock.

Wall Street Analysts Forecast Growth

HCA has been the subject of a number of research analyst reports. Truist Financial upped their target price on HCA Healthcare from $520.00 to $546.00 and gave the stock a “buy” rating in a research report on Wednesday, January 28th. Barclays boosted their price target on shares of HCA Healthcare from $494.00 to $551.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 28th. Oppenheimer lifted their price objective on shares of HCA Healthcare from $500.00 to $540.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 28th. The Goldman Sachs Group raised their target price on shares of HCA Healthcare from $520.00 to $558.00 and gave the stock a “buy” rating in a report on Wednesday, January 28th. Finally, Argus increased their price objective on HCA Healthcare from $530.00 to $560.00 and gave the company a “buy” rating in a research report on Friday. Sixteen analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $523.27.

About HCA Healthcare

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.